BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1315 related articles for article (PubMed ID: 18191732)

  • 1. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial.
    Okonko DO; Grzeslo A; Witkowski T; Mandal AK; Slater RM; Roughton M; Foldes G; Thum T; Majda J; Banasiak W; Missouris CG; Poole-Wilson PA; Anker SD; Ponikowski P
    J Am Coll Cardiol; 2008 Jan; 51(2):103-12. PubMed ID: 18191732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous iron alone for the treatment of anemia in patients with chronic heart failure.
    Bolger AP; Bartlett FR; Penston HS; O'Leary J; Pollock N; Kaprielian R; Chapman CM
    J Am Coll Cardiol; 2006 Sep; 48(6):1225-7. PubMed ID: 16979010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ferric carboxymaltose in patients with heart failure and iron deficiency.
    Anker SD; Comin Colet J; Filippatos G; Willenheimer R; Dickstein K; Drexler H; Lüscher TF; Bart B; Banasiak W; Niegowska J; Kirwan BA; Mori C; von Eisenhart Rothe B; Pocock SJ; Poole-Wilson PA; Ponikowski P;
    N Engl J Med; 2009 Dec; 361(25):2436-48. PubMed ID: 19920054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival.
    Okonko DO; Mandal AK; Missouris CG; Poole-Wilson PA
    J Am Coll Cardiol; 2011 Sep; 58(12):1241-51. PubMed ID: 21903058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous iron without erythropoietin for the treatment of iron deficiency anemia in patients with moderate to severe congestive heart failure and chronic kidney insufficiency.
    Usmanov RI; Zueva EB; Silverberg DS; Shaked M
    J Nephrol; 2008; 21(2):236-42. PubMed ID: 18446719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
    Ponikowski P; Anker SD; Szachniewicz J; Okonko D; Ledwidge M; Zymlinski R; Ryan E; Wasserman SM; Baker N; Rosser D; Rosen SD; Poole-Wilson PA; Banasiak W; Coats AJ; McDonald K
    J Am Coll Cardiol; 2007 Feb; 49(7):753-62. PubMed ID: 17306703
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia.
    Palazzuoli A; Silverberg D; Iovine F; Capobianco S; Giannotti G; Calabrò A; Campagna SM; Nuti R
    Am Heart J; 2006 Dec; 152(6):1096.e9-15. PubMed ID: 17161060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot evaluation of the long-term effect of combined therapy with intravenous iron sucrose and erythropoietin in elderly patients with advanced chronic heart failure and cardio-renal anemia syndrome: influence on neurohormonal activation and clinical outcomes.
    Comín-Colet J; Ruiz S; Cladellas M; Rizzo M; Torres A; Bruguera J
    J Card Fail; 2009 Nov; 15(9):727-35. PubMed ID: 19879457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationale and design of the IRON-HF study: a randomized trial to assess the effects of iron supplementation in heart failure patients with anemia.
    Beck-da-Silva L; Rohde LE; Pereira-Barretto AC; de Albuquerque D; Bocchi E; Vilas-Boas F; Moura LZ; Montera MW; Rassi S; Clausell N
    J Card Fail; 2007 Feb; 13(1):14-7. PubMed ID: 17338998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement of anemia with erythropoietin and intravenous iron reduces sleep-related breathing disorders and improves daytime sleepiness in anemic patients with congestive heart failure.
    Zilberman M; Silverberg DS; Bits I; Steinbruch S; Wexler D; Sheps D; Schwartz D; Oksenberg A
    Am Heart J; 2007 Nov; 154(5):870-6. PubMed ID: 17967592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency.
    Charles-Edwards G; Amaral N; Sleigh A; Ayis S; Catibog N; McDonagh T; Monaghan M; Amin-Youssef G; Kemp GJ; Shah AM; Okonko DO
    Circulation; 2019 May; 139(21):2386-2398. PubMed ID: 30776909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are hematinic deficiencies the cause of anemia in chronic heart failure?
    Witte KK; Desilva R; Chattopadhyay S; Ghosh J; Cleland JG; Clark AL
    Am Heart J; 2004 May; 147(5):924-30. PubMed ID: 15131553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia.
    Beck-da-Silva L; Piardi D; Soder S; Rohde LE; Pereira-Barretto AC; de Albuquerque D; Bocchi E; Vilas-Boas F; Moura LZ; Montera MW; Rassi S; Clausell N
    Int J Cardiol; 2013 Oct; 168(4):3439-42. PubMed ID: 23680589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study.
    Van Craenenbroeck EM; Conraads VM; Greenlaw N; Gaudesius G; Mori C; Ponikowski P; Anker SD
    Eur J Heart Fail; 2013 Jul; 15(7):756-62. PubMed ID: 23639779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial.
    Al RA; Unlubilgin E; Kandemir O; Yalvac S; Cakir L; Haberal A
    Obstet Gynecol; 2005 Dec; 106(6):1335-40. PubMed ID: 16319260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
    Mircescu G; Gârneata L; Capusa C; Ursea N
    Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications.
    Bailie GR
    Arzneimittelforschung; 2010; 60(6a):386-98. PubMed ID: 20648930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
    Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
    J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large-dose intravenous ferric carboxymaltose injection for iron deficiency anemia in heavy uterine bleeding: a randomized, controlled trial.
    Van Wyck DB; Mangione A; Morrison J; Hadley PE; Jehle JA; Goodnough LT
    Transfusion; 2009 Dec; 49(12):2719-28. PubMed ID: 19682342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 66.